The rise of artificial intelligence has been popular within the life sciences industry and in particular pharma. Find out why and what it means for the future of drug development.
The recent surge in activity in deploying AI capabilities in pharmaceutical R&D shows no sign of abating, with ‘big pharma’ investing significant capital in streamlining or accelerating the drug discovery process and applying AI methods to identifying new targets and medicines. If AI delivers on its promise, then there will be a material increase in the rate of new medicines coming to market. This could lead to a corresponding up-tick in the demands on manufacturing. Running in parallel is the question of how the same technologies can be applied to increase efficiency and improve outcomes in manufacturing as well as how AI technology might help improve efficiencies within these businesses.
AI meets ‘big pharma’